TABLE 1

18F-Fluciclovine Activity Correlated to Demographic, Histologic, and Immunohistochemical Characteristics

18F-Fluciclovine uptake (SUVmax) (min)
Subject no.Age (y)Location of breast lesionSize (cm)TNMHistologic diagnosisKi-67 (%)5172941
163RUO1.5 × 1.2 × 1.0T1cNxM0IDC NG2; ER+/PR+/HER2−High (21)5.65.14.83.6
RUIDiffuseNAStable posttherapy scar*NA1.21.41.51.4
250RUI2.5 × 2.0 × 0.3NADuctal hyperplasia and columnar cells with microcalcificationsNA2.01.81.81.5
367LUI1.1 × 1T1N0M0IDC NG1; ER+/PR+HER2−High (29)9.77.46.66.1
477RUO2.0T1cN1aM0IDC NG2; ER+/PR−/HER2+Intermediate (11)3.03.84.04.2
RUO0.7NAFibroadipose tissueNA0.60.60.50.3
560RLO1.4 × 1.2 × 1.5T1N0M0ILC NG2; ER+/PR+/HER2−High (45)3.93.33.43.5
LUI3.2 × 1.5 × 1.9T2N1M1IDC NG3; ER+/PR−/HER2−High (97)7.98.38.28.2
654RUI15.1 × 14.7 × 15.2T4cN1M0IMC; ER−/PR−/HER2−High (62)8.68.98.99.1
Left subareaolar1.8NAFibrocystic change, apocrine metaplasia, and focal ductal hyperplasiaNA1.21.11.11.2
760LLI2.0 × 1.5 × 1.4T1cN0M0IDC NG3; ER+/PR−/HER2−High (95)7.56.25.45.0
889LUO3.0 × 2.8 × 2.1T2N0M0IDC NG3; ER+/PR+/HER2−High (40)8.89.39.39.3
Right axillary tail2.3 × 2.2 × 1.9T2N0M0IDC NG3; ER−/PR−/HER2−High (34)11.712.310.311.0
968LUO15.4T3NxM0ILC NG2; ER+/PR+/HER2−High (39)6.66.45.95.5
1054RUO1.5T1N1M0ILC NG1; ER+/PR−/HER2−High (15)2.22.01.71.8
1173LUO4 × 3.2 × 1.3T2N0M0ILC NG1; ER+/PR+/HER2−Low (2)2.63.23.43.6
1249LUO5.5 × 4.6T3N2aM0ILC NG2; ER+/PR+/HER2−High (25)3.54.54.54.9
  • *Confirmed on conventional imaging.

  • RUO = right upper outer; NG = Nottingham grade; RUI = right upper inner; NA = not applicable; LLI = left lower inner; RLO = right lower outer; LUI = left upper inner; LUO = left upper outer.